Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. Richard A. Miller, M.D., president and CEO, and Jeffrey Arcara, chief business officer, will represent the company.
Key points:
- One-on-one meetings with investors scheduled
- Corporate overview presentation on September 10 at 12:00pm ET
- Live webcast available, accessible for 90 days post-event
- Webcast link provided in the investor relations section of Corvus website
This conference participation highlights Corvus Pharmaceuticals' efforts to engage with investors and showcase their latest developments in the biopharmaceutical industry.
Corvus Pharmaceuticals (NASDAQ: CRVS), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 26esima Conferenza Annuale Globale sugli Investimenti H.C. Wainwright a New York dal 9 all'11 settembre 2024. Richard A. Miller, M.D., presidente e CEO, e Jeffrey Arcara, direttore commerciale, rappresenteranno l'azienda.
Punti chiave:
- Incontri individuali programmati con gli investitori
- Presentazione aziendale il 10 settembre alle 12:00 ET
- Webcast dal vivo disponibile, accessibile per 90 giorni dopo l'evento
- Link al webcast fornito nella sezione relazioni con gli investitori del sito web di Corvus
Questa partecipazione alla conferenza evidenzia gli sforzi di Corvus Pharmaceuticals per coinvolgere gli investitori e mostrare i loro ultimi sviluppi nel settore biofarmaceutico.
Corvus Pharmaceuticals (NASDAQ: CRVS), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright en Nueva York del 9 al 11 de septiembre de 2024. Richard A. Miller, M.D., presidente y CEO, y Jeffrey Arcara, director comercial, representarán a la compañía.
Puntos clave:
- Reuniones uno a uno con inversores programadas
- Presentación general de la empresa el 10 de septiembre a las 12:00 p.m. ET
- Webcast en vivo disponible, accesible durante 90 días después del evento
- Enlace al webcast proporcionado en la sección de relaciones con inversores del sitio web de Corvus
Esta participación en la conferencia destaca los esfuerzos de Corvus Pharmaceuticals por involucrar a los inversores y mostrar sus últimos desarrollos en la industria biofarmacéutica.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 임상 단계의 생명공학 회사로서 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. Richard A. Miller, M.D., 회장 겸 CEO, 및 Jeffrey Arcara, 최고 비즈니스 책임자가 회사를 대표할 예정입니다.
주요 사항:
- 투자자와의 일대일 미팅 예정
- 9월 10일 오후 12시 ET에 기업 개요 발표 예정
- 이벤트 후 90일 동안 접근 가능한 생중계 제공
- Corvus 웹사이트의 투자자 관계 섹션에 생중계 링크 제공
이번 회의 참가를 통해 Corvus Pharmaceuticals는 투자자와 소통하고 생명공학 산업의 최신 개발 사항을 선보이기 위한 노력을 강조합니다.
Corvus Pharmaceuticals (NASDAQ: CRVS), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright à New York du 9 au 11 septembre 2024. Richard A. Miller, M.D., président-directeur général, et Jeffrey Arcara, directeur commercial, représenteront la société.
Points clés :
- Des réunions individuelles avec des investisseurs sont prévues
- Présentation de l'entreprise le 10 septembre à 12h00 ET
- Webdiffusion en direct disponible, accessible pendant 90 jours après l'événement
- Le lien de la webdiffusion est fourni dans la section des relations investisseurs du site web de Corvus
Cette participation à la conférence met en lumière les efforts de Corvus Pharmaceuticals pour interagir avec les investisseurs et présenter leurs dernières avancées dans l'industrie biopharmaceutique.
Corvus Pharmaceuticals (NASDAQ: CRVS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York vom 9. bis 11. September 2024 angekündigt. Richard A. Miller, M.D., Präsident und CEO, sowie Jeffrey Arcara, Chief Business Officer, werden das Unternehmen vertreten.
Wichtige Punkte:
- Einzelgespräche mit Investoren sind geplant
- Unternehmensübersicht-Präsentation am 10. September um 12:00 Uhr ET
- Live-Webcast verfügbar, 90 Tage nach der Veranstaltung zugänglich
- Webcast-Link in der Investor Relations-Sektion der Corvus-Website bereitgestellt
Diese Teilnahme an der Konferenz hebt die Bemühungen von Corvus Pharmaceuticals hervor, mit Investoren in Kontakt zu treten und ihre neuesten Entwicklungen in der biopharmazeutischen Industrie zu präsentieren.
- None.
- None.
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company’s presentation will be on Tuesday, September 10 at 12:00pm ET.
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When is Corvus Pharmaceuticals (CRVS) presenting at the H.C. Wainwright Global Investment Conference?
Who will represent Corvus Pharmaceuticals (CRVS) at the H.C. Wainwright conference?
How long will the webcast of Corvus Pharmaceuticals' (CRVS) presentation be available?
Where can investors access the webcast of Corvus Pharmaceuticals' (CRVS) presentation?
